Population-Based Validation of the Prognostic Model ADJUVANT! for Early Breast Cancer
Top Cited Papers
- 20 April 2005
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 23 (12), 2716-2725
- https://doi.org/10.1200/jco.2005.06.178
Abstract
Purpose Adjuvant! ( www.adjuvantonline.com ) is a web-based tool that predicts 10-year breast cancer outcomes with and without adjuvant systemic therapy, but it has not been independently validated. Methods Using the British Columbia Breast Cancer Outcomes Unit (BCOU) database, demographic, pathologic, staging, and treatment data on 4,083 women diagnosed between 1989 and 1993 in British Columbia with T1-2, N0-1, M0 breast cancer were abstracted and entered into Adjuvant! to calculate predicted 10-year overall survival (OS), breast cancer–specific survival (BCSS), and event-free survival (EFS) for each patient. Individual BCOU observed outcomes at 10 years were independently determined. Predicted and observed outcomes were compared. Results Across all 4,083 patients, 10-year predicted and observed outcomes were within 1% for OS, BCSS, and EFS (all P > .05). Predicted and observed outcomes were within 2% for most demographic, pathologic, and treatment-defined subgroups. Adjuvant! overestimated OS, BCSS, and EFS in women younger than age 35 years (predicted − observed = 8.6%, 9.6%, and 13.6%, respectively; all P < .001) or with lymphatic or vascular invasion (LVI; predicted − observed = 3.6%, 3.8%, and 4.2%, respectively; all P < .05); these two prognostic factors were not automatically incorporated within the Adjuvant! algorithm. After adjusting for the distribution of LVI, using the prognostic factor impact calculator in Adjuvant!, 10-year predicted and observed outcomes were no longer significantly different. Conclusion Adjuvant! performed reliably. Patients younger than age 35 or with known additional adverse prognostic factors such as LVI require adjustment of risks to derive reliable predictions of prognosis without adjuvant systemic therapy and the absolute benefits of adjuvant systemic therapy.This publication has 18 references indexed in Scilit:
- Helping Patients Make Informed Choices: A Randomized Trial of a Decision Aid for Adjuvant Chemotherapy in Lymph Node-Negative Breast CancerJNCI Journal of the National Cancer Institute, 2003
- Infopoints: A web-based system for individualised survival estimation in breast cancerBMJ, 2003
- Understanding the Utility of Adjuvant Systemic Therapy for Primary Breast CancerJournal of Clinical Oncology, 2001
- Computer Program to Assist in Making Decisions About Adjuvant Therapy for Women With Early Breast CancerJournal of Clinical Oncology, 2001
- Polychemotherapy for early breast cancer: an overview of the randomised trialsThe Lancet, 1998
- Tamoxifen for early breast cancer: an overview of the randomised trialsThe Lancet, 1998
- Survey of breast cancer patients concerning their knowledge and expectations of adjuvant therapy.Journal of Clinical Oncology, 1998
- The association between population-based treatment guidelines and adjuvant therapy for node-negative breast cancerBritish Journal of Cancer, 1997
- Prognostic factors of breast recurrence in the conservative management of early breast cancer: A 25-year follow-upInternational Journal of Radiation Oncology*Biology*Physics, 1989
- Doctor-patient communication about breast cancer adjuvant therapy.Journal of Clinical Oncology, 1989